Experiencing night blindness
Diagnosis at age 10
Legally blind by age 36
Family history of RPGR mutation
The focus is on investigational genetic therapies to restore visual function in patients with rare inherited retinal conditions.
Your patient may qualify to participate in the VISTA clinical trial, a phase 2/3 study evaluating an investigational gene therapy for the treatment of retinitis pigmentosa. Patients must meet the following criteria:
Diagnosis of XLRP confirmed by a healthcare professional
Have a mutation in the RPGR gene confirmed by genetic testing
Male ages 13-50 years
The VISTA clinical trial is currently pre-screening male patients between the ages of 13-50 (inclusive) diagnosed with X-linked retinitis pigmentosa (XLRP).
learn more
Genetic testing is critical to the diagnosis of patients with Inherited Retinal Disease. Learn more about the free genetic testing that may be available for your patients.
learn more
Gene therapy targets the exact cause of a disease and aims to treat the disease through a one-time administration.
learn more
AGTC is a biotechnology company seeking to transform the lives of patients with rare and debilitating eye diseases through its proprietary gene therapy platform.
Our team includes industry-leading experts and innovative thinkers working together on discoveries that we hope will transform the lives of people with rare inherited eye disorders. In particular, we are studying how to use our gene therapy platform to develop investigational treatments for disorders that are caused by single-gene mutations and that also have a significant effect on a person’s sight.
Learn more about AGTC and their groundbreaking investigational gene therapies for patients with rare diseases.
Learn more at agtc.com
To enter the site, please indicate that you are a Healthcare Professional